🧬 BIOTECH CATALYST AI SCANNER – January WK4

Alex

26 Jan 2026 — 17 min read

The biotech sector enters Q1 2026 with renewed optimism as XBI hovers around $120-131, digesting strong 2025 gains that saw the equal-weight ETF outperform the broader health sector. Dealmaking chatter continues to drive sentiment, with Mizuho analysts pointing to sustained M&A activity as big pharma fills pipelines through acquisition. Small-cap catalysts remain the heartbeat of the sector.

This week's scanner analyzed 30 clinical-stage companies with catalysts in the next 7-90 days—10 featured for deep-dive treatment, 20 watchlist for monitoring. Phase 3 readouts dominate Q1 calendars, with several pressure cooker setups where runway meets data timing. The theme: cash-strapped companies racing against dilution clocks while deep value names trading below cash offer asymmetric optionality.

What We're Tracking:

Trading Below Cash: ACET, ACRV, TCRX, BCYC, FGEN (💰 Negative EV setups)
Strong Runway: ANRO, ACRV, WVE, TARA, PALI, APGE, FGEN (🏰 36mo+ runway)
Critical Window: MBRX, CLSD, PCSA, QNCX, BFRI, SKYE, SPRB (⚠️ Cash crunch meets catalyst)
Virgin Data: ACET, ALMS, OCUL, MBRX, KPTI, ANRO, QNCX, PVLA, KOD, PALI, IRD (🔥 First-time readouts)
High Momentum: ACET, ALMS, LSTA, ADAG, TCRX, BFRI, ONCY (🚀 +20% 21-day moves)

FEATURED ANALYSIS (#1-10)

#1. ACET – Adicet Bio Inc.

🎯 THE CATALYST
Event: ADI-001 – Phase 2 in Lupus nephritis and Systemic Lupus Erythematosus (SLE)
Date: 2026-03-31
🛡️ FDA Status: FTD
⭐ BSI SCORE: 8.06/10

Market ignores Adicet Bio's gamma delta T-cell stealth in ADI-001, slipping past immune rejection radars to reset lupus chaos—pure underdog firepower overlooked at $81M cap with $154M cash fortress.

The Setup: Valuation gap screams hidden value: $81M market cap ignores negative EV and virgin Phase 1 data where all 7 lupus patients slashed SLEDAI-2K scores rapidly. Healthy 18mo+ runway, +500% 21d momentum, low float fuel this beneath-the-radar deep value play.

Science & Edge: ADI-001's allogeneic gamma delta T cells obliterated disease activity in Phase 1: every one of 7 evaluable LN/SLE patients hit rapid, sustained SLEDAI-2K and PGA drops. FTD designation spotlights this off-the-shelf edge in autoimmunity, untouched by NK cell traps. The gamma delta approach solves the manufacturing and rejection issues plaguing autologous CAR-T competitors—cells can be manufactured in advance and administered without patient-specific customization.

Risk/Reward:
🐂 Bull: FDA meeting 1Q26 greenlights Phase 2 in 2Q26; success catapults to analyst highs of $136+, unlocking 15x from $8.44.
🐻 Bear: Phase 2 flops erase cash burn to 2027 end; dilution or trial delays crush to sub-$3 lows.

#2. ALMS – Alumis Inc.

🎯 THE CATALYST
Event: ESK-001 (ONWARD3) – Phase 3 in Moderate-to-severe plaque psoriasis
Date: 2026-03-31
⭐ BSI SCORE: 7.93/10

Alumis commands the allosteric TYK2 frontier, surging past orthosteric rivals with ESK-001's precision oral dosing for plaque psoriasis, backed by $532M cash fueling Phase 3 acceleration.

The Setup: ALMS surges with 21d momentum at +114.1%, RSI 85.2 signaling overbought strength, high momentum, and virgin Phase 3 data ahead—leading the pack as institutional eyes lock in on 1Q26 readout. Overbought conditions warrant caution on entry timing, but the fundamental setup remains intact.

Science & Edge: ESK-001 allosterically locks TYK2, dodging JAK1 toxicity; Phase 2 OLE at EADV 2024 showed 40mg BID yielding most patients at PASI 75, well-tolerated over 28 weeks—outpacing rivals' broader JAK inhibitors. The allosteric mechanism offers selectivity that orthosteric TYK2 inhibitors like Bristol's Sotyktu cannot match, potentially eliminating liver monitoring requirements.

Risk/Reward:
🐂 Bull: Phase 3 hits PASI 75, revaluation continues further towards analysts' average target price of $35.
🐻 Bear: Data misses PASI 75, cash burn erodes runway, drops to 52-week low $2.76.

#3. OCUL – Ocular Therapeutix Inc.

🎯 THE CATALYST
Event: AXPAXLI (OTX-TKI) SOL-1 – Phase 3 in Wet Age-related Macular Degeneration (AMD)
Date: 2026-03-31
⭐ BSI SCORE: 7.61/10

Ocular Therapeutix surges ahead with bioresorbable hydrogel tech commanding sustained drug delivery in the eye, outpacing rivals in wet AMD treatment duration and efficacy.

The Setup: OCUL commands attention with RSI at 31.1 signaling near oversold territory amid high-velocity setup and virgin Phase 3 data on horizon. Negative 21d momentum of -19.4% masks accumulating interest as $278M cash fuels runway past 12 months toward 1Q26 readout. FDA's SPA amendment provides regulatory alignment.

Science & Edge: AXPAXLI (OTX-TKI) delivers sustained TKI via hydrogel implant, targeting wet AMD with Phase 3 SOL-1 pivotal trial. Outpaces Eylea's 8-week interval with potential 6-9 month durability, reducing injection burden dramatically—a massive quality-of-life improvement for AMD patients who currently require monthly or bi-monthly injections.

Risk/Reward:
🐂 Bull: Phase 3 success triggers NDA, propelling shares to analyst targets of $22-31 (97-120% upside from $11).
🐻 Bear: Trial failure craters stock to $6 lows, eroding cash amid -$196M FCF burn into 2027.

#4. MBRX – Moleculin Biotech Inc.

🎯 THE CATALYST
Event: Annamycin (MIRACLE) – Phase 1/2 in Acute myeloid leukemia (AML)
Date: 2026-03-31
⭐ BSI SCORE: 7.45/10

Cash at $3.73M with 1-month runway faces Q1 2026 unblinding—Annamycin's cardiotoxicity-free profile in five trials targets R/R AML void, targeting what anthracyclines failed to solve.

The Setup: 1-month cash countdown collides with Q1 MIRACLE unblinding from 45 subjects—⚠️ cash crunch, 📈 RSI 75 overbought, 📊 +12.8% momentum, 🔥 virgin Phase 3 data, 🎰 low float demand this decisive moment. This is pure sink-or-swim setup.

Science & Edge: Annamycin plus cytarabine (AnnAraC) in pivotal Phase 3 MIRACLE: 30 subjects at 190mg/m² or 230mg/m² vs 15 HiDAC controls; no cardiotoxicity below FDA lifetime anthracycline max across five trials, prior Phase 1B/2 CR rates drove FDA-aligned design. Cardiotoxicity limits current anthracyclines—Annamycin's clean cardiac profile could unlock treatment for patients who've hit lifetime toxicity caps.

Risk/Reward:
🐂 Bull: MIRACLE unblinding shows Annamycin arm CR beat, funds Phase B (222 subjects), $12.61M cap rockets 10x+ on survival edge.
🐻 Bear: Dilution or shutdown in 1mo absent rescue; 45-subject data misses, trial halts, sub-$5M cap to zero.

#5. CLSD – Clearside Biomedical Inc.

🎯 THE CATALYST
Event: RGX-314 (ALTITUDE) – NDA Filing in Diabetic retinopathy
Date: 2026-02-28
⭐ BSI SCORE: 7.43/10

Clearside engineers sustained gene therapy delivery to the retina via suprachoroidal injection—bypassing the blood-retinal barrier entirely. RGX-314 targets diabetic retinopathy with durable anti-VEGF suppression, eliminating monthly injections for responders.

The Setup: Countdown to existential catalyst: FDA BLA decision in 32 days with zero cash runway. Technicals scream capitulation (RSI 9.5, -89% momentum). Stock trades at $0.86–$3.80 across venues. Success unlocks $60–$90 targets (Street consensus). Failure means dilution or death. This is the sharpest edge setup in the scan.

Science & Edge: Phase 2 CAMPSIITE pivotal sustained >80% reduction in central subfield thickness at 12 months. 78% remained injection-free post-treatment; 97% reduction in anti-VEGF burden. No intraocular inflammation at therapeutic dose (1×10¹² GC). Suprachoroidal delivery bypasses systemic absorption—mechanism competitors cannot replicate without platform licensing.

Risk/Reward:
🐂 Bull: BLA approval February 2026 unlocks diabetic retinopathy market (10M+ US patients). $60–$90 12-month price targets imply 7,000%+ upside from trough.
🐻 Bear: FDA denies or delays BLA beyond 2026. Cash depleted—capital raise at distressed valuations imminent.

#6. PCSA – Processa Pharmaceuticals Inc.

🎯 THE CATALYST
Event: NGC-Capecitabine (PCS6422) – Phase 2 in Breast cancer
Date: 2026-03-31
⭐ BSI SCORE: 7.36/10

Processa engineers capecitabine metabolism via PCS6422 to boost cancer-killing anabolites and slash toxic catabolites in a high-stakes race against cash depletion.

The Setup: With $1.74M cash and 1-month runway, the countdown hits critical: Phase 2 interim data must deliver by Q1 2026 or PCSA dies. Cash crunch ⚠️ and low float 🎰 amplify this decisive moment. No margin for error on either data or financing fronts.

Science & Edge: PCS6422 inhibits DPD, lifting cancer-killing metabolite exposure in 16/19 patients vs mono-capecitabine, while side effect severity stays comparable—no HFS escalation. 150mg BID dosing sustains safety amid higher active metabolite load. The DPD inhibition approach transforms capecitabine's therapeutic index, potentially enabling higher effective doses without increased toxicity.

Risk/Reward:
🐂 Bull: Interim data confirms efficacy boost; dilution or partnership extends runway, spiking $7.39M cap 5-10x on low float.
🐻 Bear: Data misses or toxicity flags kill momentum; 1-month cash vanishes, delisting at zero.

#7. KPTI – Karyopharm Therapeutics Inc.

🎯 THE CATALYST
Event: Selinexor (SENTRY) – Phase 3 in JAK inhibitor-naïve myelofibrosis
Date: 2026-03-31
🛡️ FDA Status: FTD
⭐ BSI SCORE: 7.33/10

Karyopharm leverages its XPO1 inhibitor platform across myelofibrosis, endometrial cancer and beyond, with selinexor approved in three U.S. oncology indications and 50+ ex-U.S. territories, fueling pipeline breadth through technology reuse in multiple front-line combos.

The Setup: Karyopharm's platform deploys selinexor across assets, with Phase 3 SENTRY enrollment complete September 2025 and topline data due March 2026—virgin data on 306 patients. Healthy runway past Q2 2026 backs the readouts. FTD designation provides regulatory tailwind.

Science & Edge: Selinexor 60mg weekly plus ruxolitinib targets XPO1 inhibition in JAKi-naïve myelofibrosis, hitting co-primaries of ≥35% spleen volume reduction at week 24 and symptom score change over 24 weeks in 2:1 randomized trial of 306 patients. XPO1 inhibition blocks nuclear export of tumor suppressor proteins, offering synergy with JAK inhibition.

Risk/Reward:
🐂 Bull: SENTRY succeeds on SVR35 and symptoms, yielding first approved MF combo and label expansion; $121M cap triples to $360M+ on approval path.
🐻 Bear: SENTRY misses endpoints, eroding cash to near-zero by mid-2026 with $38M on hand and no near-term revenue offset.

#8. LSTA – Lisata Therapeutics Inc.

🎯 THE CATALYST
Event: LSTA1 (ASCEND) – Phase 2b in 1L metastatic pancreatic ductal adenocarcinoma
Date: 2026-03-31
⭐ BSI SCORE: 7.29/10

Lisata commands the pancreatic cancer frontier with LSTA1, a peptide surging tumor access to therapies. Technical strength shines: 45.2% ORR vs 19% control, outpacing standards in metastatic PDAC.

The Setup: LSTA surges with RSI at 90.9, 21d momentum +98.6%, commanding overbought highs on low float. High momentum accelerates shares, drawing institutional eyes ahead of Phase 2b final OS data. Overbought conditions suggest consolidation risk, but fundamentals support the move.

Science & Edge: LSTA1 boosts gemcitabine/nab-paclitaxel penetration, delivering 45.2% ORR versus 19% placebo in ASCEND Phase 2b. mOS hit 10.32 months, leading combo efficacy in 1L metastatic PDAC per ESMO GI data. LSTA1 disrupts the tumor stroma, allowing chemotherapy to penetrate the notoriously therapy-resistant pancreatic cancer microenvironment.

Risk/Reward:
🐂 Bull: Phase 2b OS success triggers partnerships, rocketing to analyst $23.50 target (+851%).
🐻 Bear: Trial misses or cash burn to 2027 floor shares under $2 amid dilution risks.

#9. ANRO – Alto Neuroscience Inc.

🎯 THE CATALYST
Event: ALTO-101 – Phase 2 in Schizophrenia
Date: 2026-03-31
🛡️ FDA Status: FTD
⭐ BSI SCORE: 7.27/10

Cash-rich Alto Neuroscience deploys precision EEG biomarkers to match ALTO-101, a PDE4 inhibitor, to schizophrenia patients with theta response, securing multi-year runway for targeted psychiatry advances.

The Setup: With $184.2M cash post-PIPE, runway extends into 2028. Strong runway edge anchors stability amid -15.5% 21d momentum and virgin Phase 2 data for ALTO-101 in 1Q 2026, yielding optionality across four readouts. The multi-year runway provides rare luxury in biotech: patience.

Science & Edge: ALTO-101 targets PDE4 inhibition for schizophrenia CIAS; Phase 1 validated 100% EEG theta response biomarker in PK checks, preclinical SOBP data confirm translational robustness (April 2025), enrollment ongoing to 1Q 2026 topline. The biomarker-driven approach aims to enrich for responders, potentially avoiding the dilution of effect that has doomed prior CNS trials.

Risk/Reward:
🐂 Bull: Positive Phase 2 theta biomarker hit drives ALTO-101 forward; $184M funds parallel readouts into 2028, multiple shots on goal lift shares 2-3x.
🐻 Bear: Trial miss erodes confidence in biomarker; cash burn accelerates to $40-50M/year, shares drop to $3-4 on financing risk.

#10. QNCX – Quince Therapeutics Inc.

🎯 THE CATALYST
Event: EryDex (NEAT) – Phase 3 in Ataxia-Telangiectasia (A-T)
Date: 2026-03-31
🛡️ FDA Status: FTD
⭐ BSI SCORE: 6.96/10

Cash-strapped biotech racing to deliver first-ever A-T therapy via erythrocyte-encapsulated DSP, after acquiring EryDel. 7,800+ infusions in 425 patients show no chronic steroid toxicities.

The Setup: 4-month cash runway burns to zero before 1Q26 topline readout—critical window slams shut. ⚠️ Cash crunch meets 📉 -16.1% 21d momentum; must-deliver virgin Phase 3 data or face oblivion. FTD designation offers accelerated path if data hits.

Science & Edge: eDSP traps dexamethasone in patient's red blood cells for monthly IV infusion, slashing adrenal suppression vs free steroid. 188 patients treated ≥12 months, zero long-term corticosteroid toxicities; 105 enrolled in NEAT (83 ages 6-9), RmICARS endpoint at 6 months. The autologous approach—using patient's own red blood cells as drug carriers—eliminates immunogenicity concerns.

Risk/Reward:
🐂 Bull: NEAT hits on ataxia scale, Fast Track to approval; $172M cap rockets 5-10x on orphan exclusivity.
🐻 Bear: Data miss triggers dilution or bankruptcy; $13M cash evaporates, shares to pennies.

WATCHLIST (#11-30)

#11. ADAG – Adagene Inc. [Oncology]

📊 Price: $2.49 | Cap: $117.36M | Cash: $85.19M | RSI: 67.2 | Momentum: +34.59% 🎯 Muzastotug (ADG126) + KEYTRUDA – Phase 2 in Solid tumors (2026-03-31) 🛡️ FTD ⭐ BSI: 6.83/10

The Intel: Targets checkpoint-resistant MSS colorectal cancer with a CTLA-4 masking antibody designed to activate only within tumors, reducing systemic toxicity that limits standard CTLA-4 approaches. FDA Fast Track for MSS CRC without active liver mets positions for accelerated review. Primary risk: Phase 2 dose expansion data interpretation in heterogeneous solid tumor population.

#12. PVLA – Palvella Therapeutics Inc. [Rare Disease / Specialty]

📊 Price: $85.30 | Cap: $1.01B | Cash: $53.24M | RSI: 38.64 | Momentum: -14.93% 🎯 QTORIN – Phase 3 (SELVA) in Microcystic lymphatic malformations (2026-03-31) ⭐ BSI: 6.83/10

The Intel: Advances patented 3.9% anhydrous rapamycin gel for rare skin diseases where less than 2% have FDA-approved treatments. Topical formulation bypasses systemic mTOR inhibition risks. Near-oversold RSI and virgin Phase 3 readout create contrarian entry. Primary risk: small patient population (7,600 US) limits peak revenue.

#13. ACRV – Acrivon Therapeutics Inc. [Oncology]

📊 Price: $2.05 | Cap: $64.69M | Cash: $113.15M | RSI: 42.81 | Momentum: -11.64% 🛡️ BTD, FTD ⭐ BSI: 6.73/10

The Intel: Pursues CHK1/2 inhibitor ACR-368 with OncoSignature companion diagnostic—FDA Breakthrough Device-designated—to select platinum-resistant ovarian cancer responders. Phase 2b showed 67% confirmed ORR in serous subtype BM+ patients. 💰 Negative EV ($113M cash vs $65M cap) and 24mo+ runway provide deep value cushion. Primary risk: narrow biomarker-positive population limits commercial scale.

#14. KOD – Kodiak Sciences Inc. [Ophthalmology]

📊 Price: $25.86 | Cap: $1.55B | Cash: $212.93M | RSI: 49.34 | Momentum: -5.79% ⭐ BSI: 6.69/10

The Intel: Champions tarcocimab tedromer (KSI-301) delivering every-6-month anti-VEGF dosing after 3 initiations for non-proliferative diabetic retinopathy—dramatically extending treatment intervals versus Eylea's 8-week standard. GLOW2 enrollment complete with 240 patients, virgin topline expected 1Q26. Primary risk: wet AMD competitor Phase 3 setback creates overhang on platform.

#15. BFRI – Biofrontera Inc. [Dermatology]

📊 Price: $1.00 | Cap: $11.65M | Cash: $1.41M | RSI: 90.28 | Momentum: +41.58% ⭐ BSI: 6.68/10

The Intel: Expands Ameluz (BF-200 ALA) photodynamic therapy platform from actinic keratosis into Phase 2b for moderate-to-severe acne—leveraging existing 35% YoY revenue growth and commercial infrastructure. High momentum and overbought technicals signal speculative interest. Primary risk: 1-month runway creates existential financing pressure before data.

#16. TCRX – TScan Therapeutics Inc. [Oncology]

📊 Price: $1.14 | Cap: $64.69M | Cash: $141.89M | RSI: 63.64 | Momentum: +25.18% ⭐ BSI: 6.66/10

The Intel: Pioneers TCR-T therapy TSC-202-A0201 targeting HPV16-positive solid tumors using TargetScan platform for novel T-cell target discovery. 💰 Negative EV ($142M cash vs $65M cap) anchors downside. T-Plex technology enables multiplexed attacks on cancer cells. Primary risk: early Phase 1 safety data; long path to registration.

#17. VNDA – Vanda Pharmaceuticals Inc. [Neurology / CNS]

📊 Price: $8.01 | Cap: $473.36M | Cash: $252.29M | RSI: 46.69 | Momentum: +17.11% ⭐ BSI: 6.55/10

The Intel: Awaits PDUFA decision February 21, 2026 for Bysanti (milsaperidone) in acute bipolar I disorder—a novel chemical entity bioequivalent to iloperidone across its full therapeutic dose range. No review issues identified to date. Healthy 18mo+ runway and existing commercial infrastructure (HETLIOZ franchise) enable self-launch. Primary risk: crowded bipolar market limits differentiation without new efficacy data.

#18. SKYE – Skye Bioscience Inc. [Metabolic]

📊 Price: $1.01 | Cap: $32.38M | Cash: $17.79M | RSI: 58.71 | Momentum: +18.82% ⭐ BSI: 6.54/10

The Intel: Develops peripherally restricted CB1 inhibitor nimacimab for obesity, uniquely avoiding brain exposure that caused psychiatric side effects in prior small-molecule approaches (rimonabant). Phase 2a missed primary endpoint October 2025; 26-week extension data due 1Q26 for redemption shot. Primary risk: 3-month runway and prior miss create dual financing/scientific pressure.

#19. SPRB – Spruce Biosciences Inc. [Rare Disease / Specialty]

📊 Price: $81.52 | Cap: $87.26M | Cash: $3.70M | RSI: 41.91 | Momentum: -2.65% 🛡️ BTD ⭐ BSI: 6.54/10

The Intel: Targets BLA submission 1Q26 for tralesinidase alfa—first enzyme replacement therapy for Sanfilippo Syndrome Type B. Five-year data showed normalized CSF sugar accumulation and apparent halting of cognitive decline in pediatric patients with no approved alternatives. Breakthrough Therapy designation signals FDA alignment. Primary risk: 2-month runway demands immediate financing; low float amplifies volatility.

#20. WVE – Wave Life Sciences Ltd. [Rare Disease / Specialty]

📊 Price: $13.47 | Cap: $2.42B | Cash: $487.66M | RSI: 26.43 | Momentum: -22.94% ⭐ BSI: 6.53/10

The Intel: Achieved first-ever human RNA editing in RestorAATion-2 Phase 1/2, where single WVE-006 dose raised mean total AAT to 10.8 µM at day 15 in PiZZ AATD patients. 400mg monthly multidose cohort data expected 1Q26. 📉 Oversold RSI 26 and 24mo+ runway create contrarian entry into validated platform. Primary risk: durability of AAT protein restoration and translation to clinical benefit unknown.

#21. ALDX – Aldeyra Therapeutics Inc. [Ophthalmology]

📊 Price: $5.19 | Cap: $312.24M | Cash: $66.09M | RSI: 63.4 | Momentum: +2.77% ⭐ BSI: 6.48/10

The Intel: Awaits extended PDUFA decision March 16, 2026 for reproxalap (ADX-102) in Dry Eye Disease after achieving highly significant ocular discomfort reduction (P=0.002, LSMD -6.5) in Phase 3 chamber trial. Novel RASP mechanism blocks aldehyde-mediated inflammation. Strong runway of 24mo+ provides approval path stability. Primary risk: prior FDA interactions extended timeline, suggesting possible CMC or labeling discussions.

#22. TARA – Protara Therapeutics Inc. [Oncology]

📊 Price: $6.19 | Cap: $319.59M | Cash: $191.34M | RSI: 62.54 | Momentum: +15.27% ⭐ BSI: 6.38/10

The Intel: Deploys TARA-002 TLR2/NOD2 agonist for BCG-naive high-grade NMIBC, achieving 72.4% high-grade complete response rate with no serious adverse events in ADVANCED-2. ASCO GU presentation February 27, 2026 will update durability data. 36mo+ runway and Strong Runway flag anchor long-term development. Primary risk: competitive with intravesical checkpoint inhibitors; pathway to registration unclear.

#23. PALI – Palisade Bio Inc. [Immunology / Inflammation]

📊 Price: $1.91 | Cap: $284.60M | Cash: $159.07M | RSI: 34.22 | Momentum: -8.61% ⭐ BSI: 6.35/10

The Intel: Brings targeted PDE4 inhibitor prodrug PALI-2108 for fibrostenotic Crohn's Disease in Phase 1b—an indication with zero approved anti-fibrotic therapies. 100% clinical response in UC cohort with no serious adverse events validates mechanism. Near-oversold technicals, 🔥 virgin data, and 36mo+ runway create patient-capital setup. Primary risk: early-stage with long development timeline.

#24. BCYC – Bicycle Therapeutics plc [Oncology]

📊 Price: $6.95 | Cap: $482.11M | Cash: $554.98M | RSI: 56.4 | Momentum: +0.14% 🛡️ FTD ⭐ BSI: 6.35/10

The Intel: Offers Bicycle Toxin Conjugate zelenectide pevedotin (BT8009) targeting nectin-4 in solid tumors, with SABCS 2024 reporting 60% ORR and 11.1-month median duration of response. Phase 2/3 Duravelo-2 ongoing; regulatory pathway feedback expected 1Q26. 💰 Negative EV ($555M cash vs $482M cap) plus FTD status. Primary risk: competitive pressure from Padcev (enfortumab vedotin) in nectin-4 space.

#25. FGEN – Kyntra Bio Inc. [Oncology]

📊 Price: $9.71 | Cap: $39.28M | Cash: $115.92M | RSI: 64.61 | Momentum: +4.54% ⭐ BSI: 6.34/10

The Intel: Tackles metastatic castration-resistant prostate cancer with FG-3246, a CD46-targeting antibody-drug conjugate demonstrating 8.7-month median rPFS in heavily pretreated patients. Phase 2 topline in 1Q26 for earlier treatment lines. 💰 Negative EV ($116M cash vs $39M cap), low float, and 36mo+ runway create deep value setup. Primary risk: competitive ADC landscape in mCRPC intensifying.

#26. APGE – Apogee Therapeutics Inc. [Dermatology]

📊 Price: $70.02 | Cap: $4.78B | Cash: $756.15M | RSI: 38.6 | Momentum: -9.42% ⭐ BSI: 6.32/10

The Intel: Addresses atopic dermatitis with APG777, an extended half-life anti-IL-13 antibody achieving 71.0% EASI decrease at Week 16 in Phase 2. APEX 52-week Part A data anticipated 1Q26 for durability validation. Near-oversold technicals on $4.8B cap company with 36mo+ runway suggest institutional rotation opportunity. Primary risk: crowded IL-13/IL-4 space with dupilumab dominance.

#27. CRDF – Cardiff Oncology Inc. [Oncology]

📊 Price: $2.90 | Cap: $195.35M | Cash: $46.39M | RSI: 58.82 | Momentum: -0.34% ⭐ BSI: 6.29/10

The Intel: Targets RAS-mutated metastatic colorectal cancer with PLK1 inhibitor onvansertib, achieving 49% confirmed ORR in 30mg arm versus 30% control in first-line CRDF-004. Dose-dependent responses across 30 patients support mechanism validation. 12mo+ runway provides Phase 2 update optionality in 1Q26. Primary risk: competitive with sotorasib/adagrasib in KRAS-mutant CRC; differentiation unclear.

#28. REPL – Replimune Group Inc. [Oncology]

📊 Price: $7.71 | Cap: $604.80M | Cash: $217.17M | RSI: 35.56 | Momentum: -20.68% 🛡️ BTD ⭐ BSI: 6.29/10

The Intel: Pursues PDUFA resubmission decision April 10, 2026 for RP1 (vusolimogene oderparepvec) plus OPDIVO in non-melanoma skin cancer, showing 31.4% ORR in anti-PD-1-failed melanoma. Breakthrough Therapy designation and IGNYTE-3 registration trial data support approval path. Near-oversold technicals and negative momentum create contrarian setup. Primary risk: 8-month runway and prior FDA interactions create regulatory uncertainty.

#29. IRD – Opus Genetics Inc. [Ophthalmology]

📊 Price: $2.56 | Cap: $176.55M | Cash: $45.74M | RSI: 70.37 | Momentum: +27.36% ⭐ BSI: 6.28/10

The Intel: Champions OPGx-BEST1 gene therapy delivering functional BEST1 to RPE cells via one-time subretinal injection for BEST1-related inherited retinal disease affecting 9,000 US patients with no prior treatments. Phase 1/2 BIRD-1 initial data expected 1Q26 after positive IDMC recommendation. 🔥 Virgin data with 18mo+ runway. Primary risk: early-stage gene therapy with standard development risks.

#30. ONCY – Oncolytics Biotech Inc. [Oncology]

📊 Price: $1.24 | Cap: $133.43M | Cash: $3.63M | RSI: 71.25 | Momentum: +29.98% ⭐ BSI: 6.27/10

The Intel: Leads with pelareorep oncolytic virus plus atezolizumab in GOBLET Cohort 4, achieving 30% ORR in second-line anal cancer—more than double the FDA-approved 13.8% standard of care. Type C meeting planned 1Q26 for registration pathway clarity. High momentum but ⚠️ 1-month runway creates existential financing pressure. Primary risk: immediate capital need at overbought valuations.

The Strategist's Take

This week's scan surfaces a striking dichotomy: deep value names trading below cash alongside pressure cooker setups where the clock ticks toward existential outcomes. ACET commands pole position at BSI 8.06—100% response in lupus Phase 1, $73M negative EV, and FTD designation create textbook underdog optionality. The gamma delta T-cell platform solves what has vexed CAR-T competitors: scalability and off-the-shelf availability.

The momentum plays warrant caution on entry timing. ALMS (+114% 21-day), LSTA (+98.5%), and BFRI (+41.6%) flash overbought signals, yet their underlying catalysts remain intact. Phase 3 readouts in Q1 will determine whether these moves represent smart money accumulation or retail froth. ALMS particularly intrigues—allosteric TYK2 inhibition offers a mechanistic edge that orthosteric competitors cannot match.

Cash crunch setups demand ruthless discipline. MBRX, CLSD, PCSA, and QNCX all face sub-4-month runways colliding with pivotal data. CLSD's suprachoroidal gene therapy platform shows extraordinary efficacy (78% injection-free, 97% anti-VEGF burden reduction), but RSI 9.5 and -89% momentum scream capitulation. These are pure optionality plays—position sizing must reflect the genuine possibility of zeros.

The fortress setups—ANRO, ACRV, TARA, PALI—offer patience capital can exploit. Multi-year runways eliminate financing risk while virgin data approaches. ANRO's EEG biomarker-driven approach to schizophrenia represents exactly the precision psychiatry the field has sought for decades; $175M cash through 2028 provides four shots on goal.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.